{"entity":{"id":"iberdomide","kind":"drug","name":"Iberdomide","aka":[],"tldr":"Iberdomide is a far more potent successor to lenalidomide, now in phase 3 as post-transplant maintenance and in relapsed disease.","summary":"Iberdomide is a cereblon E3 ligase modulator (CELMoD) that binds cereblon with around 20-fold higher affinity than lenalidomide, degrading Ikaros and Aiolos more completely and so killing myeloma cells and stimulating T cells more potently. Because it acts through the same pathway with greater force, it is active in lenalidomide-refractory disease: in CC-220-MM-001 the doublet with dexamethasone gave an ORR of about 26%, higher in combinations. Its main development is as post-transplant maintenance, where the phase 3 EXCALIBER-Maintenance trial against lenalidomide met its primary endpoint according to BMS reports in 2026, and in relapsed disease, where EXCALIBER-RRMM (Iber-Dd versus Dara-Vd) is ongoing. It is a more powerful successor to lenalidomide aiming to keep myeloma in remission longer after transplant.","status":"approved","asOf":"2026-09-07","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Iberdomide"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["protac-degrader","celmods"],"targets":[],"drugs":["lenalidomide"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05827016","nct04975997","nct05583617","nct06892522","nct02773030"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Zenbexus","code":"CC-220","modality":"CELMoD (cereblon E3 ligase modulator)","mechanism":"Binds cereblon with ~20-fold higher affinity than lenalidomide, degrading Ikaros/Aiolos more completely.","approvals":[{"region":"US","year":2026,"indication":"Multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent, with subcutaneous daratumumab and dexamethasone (Zenbexus, label effective 13 August 2026)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[{"date":"2026-08-13","type":"accelerated-approval","region":"US","note":"FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma The confirmatory requirement was still open 0.1 years later, when the FDA's table was read.","source":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone","indication":"In combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent"}]},"route":"/drugs/iberdomide/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"nct05583617","kind":"trial","name":"A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma","route":"/trials/nct05583617/"},{"id":"nct06892522","kind":"trial","name":"A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe","route":"/trials/nct06892522/"},{"id":"nct05827016","kind":"trial","name":"A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly","route":"/trials/nct05827016/"},{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","route":"/trials/nct02773030/"},{"id":"nct04975997","kind":"trial","name":"Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants ","route":"/trials/nct04975997/"}],"pathway":[{"id":"ubiquitin-proteasome-system","kind":"pathway","name":"Ubiquitin-proteasome system & protein homeostasis","route":"/pathways/ubiquitin-proteasome-system/"}]}}